Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.

Oncotarget · 2018 · PMC5800922 · PMID 29484130

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

a favorable trendp = 0.087so close (0.05 < p ≤ 0.1)

The estimated 7-year OS was 96% in the cohort of patients with a stable MR4.5 and 89% in the cohort of patients who did not reach such a response, with a favorable trend that has so far not reached statistical significance ( p = 0.087).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.